TEL AVIV, Israel--(BUSINESS WIRE)-- VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that the company will present preclinical data from its lead program, VB-201, at the Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases. Eyal Breitbart, Ph.D., vice president, research at VBL is scheduled to present a poster entitled “Lecinoxoids – Novel Anti-inflammatory Oxidized Phospholipids” on Monday, June 7, 2010 at 12:30 p.m. JST in Kyoto, Japan.
The Keystone Symposium on Bioactive Lipids: Biochemistry and Diseases is a forum for scientists to share their progress in lipid mediators and the translation from model systems to an understanding of their role in human physiology, disease and drug action. Keystone Symposia are recognized as catalysts for advancing biomedical and life sciences by connecting scientists within and across disciplines in an environment conducive to information exchange, the generation of new ideas, and acceleration of applications that benefit society.
VB-201 is the first in a new class of drugs and the lead candidate of several proprietary phospholipid analogs from VBL’s proprietary Lecinoxoid family that were designed to be orally available, anti-inflammatory medicines. VB-201 has successfully completed four Phase 1 clinical trials involving 120 healthy subjects under a U.S. investigational new drug (IND) application. These Phase 1 trials demonstrated that VB-201 was well tolerated with a favorable safety profile. Preclinical studies indicate that VB-201 has significant potential to treat inflammation in chronic diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and also found to bring about regression of atherosclerosis. VB-201 is currently being evaluated in a Phase 2 efficacy and safety study for the treatment of patients with psoriasis.
About VBL Therapeutics
VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents and VB-201 is the lead candidate from this program, which has entered Phase 2 clinical development in patients with psoriasis. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, the first dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2 clinical trials in 2010. The company was founded in 2000 and is based in Tel Aviv, Israel. VBL has more than 60 granted patents and more than 115 patents pending. For more information on the company, please visit www.vblrx.com.
Dan Budwick, 973-271-6085
KEYWORDS: United States Asia Pacific North America North Carolina Middle East Israel Japan
INDUSTRY KEYWORDS: Health Biotechnology Cardiology Clinical Trials Medical Devices Pharmaceutical Other Health General Health